We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAmarin Corporation PLC

Amarin Corporation PLC

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
11.64 USD -0.07 ( 0.60%)
Last update at 2026-11-12T15:47:00Z
VOLUME
13564
Market Cap
306.62M

Momentum Score

…

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11.40
Low
11.64
High
52 Week Price Range
9.44
Low
20.90
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Amarin Corporation PLC is a biopharmaceutical company whose principal marketed product, Vascepa (icosapent ethyl), is FDA‑approved to lower triglycerides and reduce cardiovascular risk. Long-term growth may be supported by continued U.S. uptake, potential label expansions, and international commercialization. The company may appeal to investors due to clinical evidence for Vascepa and a sizable addressable patient population.
Key risks include heavy reliance on a single marketed product, patent expiry and generic competition, regulatory and legal uncertainty, and pricing or reimbursement pressure that could materially reduce revenue.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.71
Dividend Yield
-
Revenue TTM
213.65M
Revenue Per Share
10.30
Gross Profit TTM
120.87M
Debt / Equity
0.03
ROE
-8.21%
Net Debt
-122.70M
ROCE
-2.93%
Diluted EPS TTM
-1.80

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -41.55M -77.20M -53.67M -103.81M 11.29M
Net income -38.80M -82.18M -59.11M -105.80M 7.73M
Selling general administrative 115.00M 72.72M 88.61M 118.80M 141.86M
Selling and marketing expenses - 79.59M 111.33M 185.61M 266.47M
Gross profit 120.87M 81.38M 165.54M 242.48M 461.86M
Reconciled depreciation 3.03M 3.01M 2.99M 3.10M 2.86M
Ebit - -77.19M -53.66M -92.34M 22.28M
Ebitda -41.54M -74.18M -50.70M -90.26M 25.14M
Depreciation and amortization - 3.01M 2.96M 2.08M 2.86M
Operating income -13.94M -91.80M -67.59M -92.34M 22.28M
Other operating expenses 196.69M 320.41M 374.50M 461.54M 558.97M
Interest expense 0.01M 0.01M 0.01M 0.01M 0.13M
Tax provision 2.75M 4.98M -5.52M 2.00M 3.56M
Interest income 10.85M 13.40M 10.02M 2.82M 1.22M
Net interest income 10.85M 13.40M 10.00M 2.80M 1.09M
Income tax expense -2.75M 4.98M 5.44M 2.00M 3.56M
Total revenue 182.75M 228.61M 306.91M 369.19M 583.19M
Total operating expenses 134.81M 173.18M 233.13M 334.83M 437.64M
Cost of revenue 61.88M 147.23M 141.37M 126.71M 121.33M
Total other income expense net -27.61M 14.60M 13.92M -11.46M -10.99M
Net income from continuing ops -38.80M -82.18M -52.48M -105.80M 7.73M
Net income applicable to common shares - - - -105.80M 7.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 670.77M 685.35M 831.68M 886.18M 1068.07M
Intangible assets 13.37M 16.39M 19.30M 21.78M 23.55M
Other current assets 24.35M 12.85M 11.62M 19.49M 22.35M
Total liab 211.49M 199.17M 279.59M 290.85M 400.97M
Total stockholder equity 459.28M 486.18M 552.10M 595.33M 667.10M
Other current liab 149.10M 139.58M 204.17M 192.68M 45.60M
Common stock 310.18M 305.30M 302.76M 299.00M 294.03M
Capital stock 310.18M 305.30M 302.76M 299.00M 294.03M
Retained earnings -1707.34M -1668.55M -1586.36M -1527.25M -1421.45M
Other liab - - - 21.35M 21.71M
Good will 13.36M - - - -
Other assets - - - 164.08M 121.71M
Cash 134.86M 121.04M 199.78M 217.67M 219.45M
Total current liabilities 194.46M 179.95M 259.28M 259.48M 370.68M
Current deferred revenue - - 2.34M 2.20M 2.65M
Net debt -122.70M -113.31M -191.04M -207.65M -210.88M
Short term debt - - - - 207.51M
Short long term debt total 12.16M 7.72M 8.74M 10.02M 8.58M
Other stockholder equity 1856.44M 1849.42M 1835.70M 1823.58M 1794.52M
Property plant equipment - - - 9.95M 9.09M
Total current assets 649.88M 595.40M 724.98M 689.10M 878.73M
Long term investments - - 0.00M 1.27M 35.00M
Net tangible assets - - - 573.55M 643.55M
Short term investments 167.93M 173.18M 121.41M 91.69M 234.67M
Net receivables 126.83M 122.28M 133.56M 130.99M 163.65M
Inventory 195.91M 166.05M 258.62M 228.73M 234.68M
Accounts payable 45.35M 40.37M 52.76M 64.60M 114.92M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 1.05M 65.95M 78.97M 164.08M 121.71M
Non current assets total 20.89M 89.95M 106.70M 197.08M 189.34M
Capital lease obligations 6.08M 7.72M 8.74M 10.02M 8.58M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 8.83M -45.98M 17.66M 175.29M 104.10M
Change to liabilities - - - -104.09M 49.59M
Total cashflows from investing activities 8.85M -45.98M -25.62M 175.29M 104.10M
Total cash from financing activities -2.04M -1.44M 0.23M -0.38M -5.07M
Change to operating activities - - - 3.78M 10.56M
Net income -38.80M -82.18M -59.34M -105.80M 7.73M
Change in cash 13.52M -78.44M -18.41M -5.18M 32.49M
Begin period cash flow 121.34M 199.78M 218.19M 223.37M 190.88M
End period cash flow 134.86M 121.34M 199.78M 218.19M 223.37M
Total cash from operating activities 6.74M -31.02M 6.91M -180.09M -66.54M
Issuance of capital stock - - - - 0.00M
Depreciation 3.03M 3.01M 2.98M 3.10M 2.86M
Other cashflows from investing activities 0.01M -45.98M 190.11M - -
Change to inventory 34.96M 105.44M 56.34M -36.42M -167.07M
Change to account receivables -3.83M 11.22M -2.33M 32.66M -9.08M
Sale purchase of stock - - -1.98M 0.60M 1.65M
Other cashflows from financing activities -2.18M -1.57M -1.99M -1.04M -5.07M
Change to netincome - - - 26.69M 38.87M
Capital expenditures 0.00M 0.00M 0.02M 0.60M 0.00M
Change in working capital 32.28M 36.17M 51.27M -104.07M -115.99M
Stock based compensation 13.94M 17.70M 15.65M 26.21M 36.94M
Other non cash items -25.54M -5.73M 12.00M 0.47M 1.93M
Free cash flow 6.74M -31.02M 6.88M -180.69M -66.54M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AMRN
Amarin Corporation PLC		 -0.07
0.60%		 11.64 - 500.00 1.44 0.67 0.05 -5.80
LLY
Eli Lilly and Company		 5.20
0.36%		 1442.49 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson		 3.95
1.41%		 284.36 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc		 1.13
0.38%		 296.11 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation		 1.60
0.33%		 486.40 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Amarin Corporation PLC

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

One Central Plaza, Dublin, Ireland, D02 K7K5

353 0 166 99020

https://www.amarincorp.com

80

Name Title Year Born
Mr. Karim Mikhail Pres, CEO & Director 1971
Dr. Steven B. Ketchum Ph.D. Pres of R&D, Exec. VP and Chief Scientific Officer 1965
Mr. Jason M. Marks J.D. Exec. VP, Chief Legal and Compliance Officer & Corp. Sec. 1976
Mr. Joseph T. Kennedy J.D. Exec. VP of Strategic Initiatives & Gen. Counsel 1968
Mr. Aaron D. Berg Exec. VP & Pres of U.S. 1963
Mr. Thomas Charles Reilly CFO & Sr. VP 1972
Dr. David Keenan Sr. VP of Technical Operations NA
Ms. Lisa M. DeFrancesco Sr. VP of Corp. Affairs & Investor Relations 1980
Alina Kolomeyer Director of Communications NA
Mr. Jordan Zwick Sr. VP of Corp. Bus. Devel. 1987

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…